Mazdutide — wholesale 10-vial kits

Research context

Mazdutide belongs to the GLP-1 / glucagon dual-agonist class. Its design draws on oxyntomodulin, a naturally occurring gut peptide that weakly activates both receptors. Mazdutide carries a fatty-acid modification that gives it a long half-life in experimental systems.

Origin and development. The peptide was designed at Eli Lilly under the code LY3305677 and is developed by Innovent Biologics, which holds rights in China, under the code IBI362. A 2026 patent-landscape review traces the program from Lilly's early peptide design through Innovent's later process-chemistry, formulation and indication-expansion work across twelve patent families. Innovent's Phase 1b studies were published in 2021 and 2022, and the Phase 3 GLORY-1 trial in the New England Journal of Medicine in 2025.

Molecular design. Oxyntomodulin is a 37-residue proglucagon product consisting of the full glucagon sequence plus an eight-residue C-terminal extension, and it activates the GLP-1 and glucagon receptors only weakly and briefly. The 34-residue mazdutide sequence registered in FDA GSRS keeps the glucagon-like N-terminal region (the TFTSDYSKYLD motif) and ends in a GPSSG-terminated segment rather than the native oxyntomodulin tail. GSRS renders non-standard residues as their parent amino acids, so the positions of non-coded residues and of the fatty-acid attachment should be read from the full GSRS record or checked against the COA's measured mass, not inferred from the one-letter string.

For researchers, the interest lies in the glucagon arm. Glucagon-receptor agonism increases hepatic energy expenditure and lipid handling in animal models, so mazdutide is used to study how adding glucagon activity changes the pharmacology of a GLP-1 agonist. It is a natural comparator for survodutide (another GLP-1 / glucagon agonist) and for triple agonists such as retatrutide in receptor-activation and hepatic-metabolism models.

Regulatory status: mazdutide received its first approval from China's National Medical Products Administration in June 2025, with a second Chinese indication added in September 2025, and it remains under clinical evaluation for further indications. It is investigational and not approved by the FDA in the United States. The mazdutide sold by WholesalePeptide.us is a research reference compound supplied only for in-vitro, analytical and preclinical laboratory research.

As a laboratory tool, mazdutide is generally run in cell lines that express a single human receptor, so that potency at the glucagon receptor and at the GLP-1 receptor can be measured separately in cAMP accumulation or reporter assays, and in rodent hepatic-metabolism models where glucagon-receptor engagement is read out through liver gene expression and circulating biomarkers rather than inferred. Its lipidation also makes it a useful test article for RP-HPLC and LC-MS methods aimed at acylated peptides.

Because mazdutide, survodutide and retatrutide are often studied side by side, labs typically need lot-matched documentation across all three so that receptor-potency comparisons are not confounded by purity or net-content differences between suppliers. Each lot we sell carries its own COA with RP-HPLC purity, an LC-MS identity mass and net peptide content, published before the lot ships, so a comparison set can be documented from a single source.

Research areas

• GLP-1 / glucagon receptor dual agonism
• Hepatic lipid and energy-expenditure models
• Oxyntomodulin analog design
• Proglucagon-derived peptide pharmacology
• Comparative pharmacology versus survodutide and retatrutide

U.S. regulatory status of the compound (as an active ingredient): Approved in China (2025) but investigational and not FDA-approved in the United States. The material sold here is a research reference chemical, not a drug product.

Handling and storage

• Store lyophilized vials at −20 °C, sealed, protected from light and moisture.
• Let the vial reach room temperature before opening to limit condensation on the powder.
• Reconstitute in a sterile buffer appropriate to the assay, following your lab's SOP.
• Aliquot reconstituted material and freeze once; avoid repeated freeze–thaw.